Barclays Maintains an 'Overweight' on Alexion Pharmaceuticals (ALXN); Raising PT to $104

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/16/2026

1. AMAT
2. GLOB
3. SPY
4. RDDT
5. HTFL
6. SNDK
7. WDAY
8. ADYEN:NA
9. DVLT
10. ADYYF

April 25, 2012 1:52 PM EDT
Get Alerts ALXN Hot Sheet
Price: $182.01 --0%

Rating Summary:
    10 Buy, 25 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Barclays maintains an 'Overweight' on Alexion Pharmaceuticals (NASDAQ: ALXN) price target raised from $84 to $104.

Analyst, Ying Huang, said, "ALXN announced revenues of $245M vs. consensus of $241M and $0.45 EPS vs. Street estimates of $0.39. The EPS beat was driven by lower costs, particularly R&D, which will go up significantly in the ensuing quarters."

Barclays raises FY12 EPS estimate from $1.68 to $1.79 and FY13 from $2.02 to $2.09.

For an analyst ratings summary and ratings history on Alexion Pharmaceuticals click here. For more ratings news on Alexion Pharmaceuticals click here.

Shares of Alexion Pharmaceuticals closed at $88.90 yesterday.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT Change

Related Entities

Barclays